Breaking News, Collaborations & Alliances

Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for FNIH

Will optimize and scale the AAV therapy processes for the treatments of CNGB1 Retinitis Pigmentosa 45 and NPHP5 retinal degeneration.

Author Image

By: Charlie Sternberg

Associate Editor

Andelyn Biosciences Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selected to manufacture adeno-associated vectors (AAV) therapies in its suspension platform for several programs under the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC).   BGTC has chosen to focus on eight rare disease programs, with Andelyn selected to optimize and scale the AAV therapy ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters